Patents Examined by Delbert R. Phillips
  • Patent number: 4849510
    Abstract: A process for producing a cancer cell-derived glycosidic related antigen having a terminal fucose glycosidic linkage structure (TCA) and a process for producing a thermally denatured TCA are provided. These TCA and thermally denatured TCA have a very high immunogenicity that cause an immune response specific to cancer cells, and exhibit an excellent effect in the treatment and prevention of cancers.
    Type: Grant
    Filed: April 4, 1985
    Date of Patent: July 18, 1989
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Masakazu Adachi
  • Patent number: 4847240
    Abstract: A method of effecting cellular uptake of molecules which are either excluded from cells or poorly transported into cells is disclosed wherein such molecules are covalently bonded to a cationic polymer which serves as a transport carrier to transport the molecules into cells.
    Type: Grant
    Filed: October 7, 1987
    Date of Patent: July 11, 1989
    Assignee: The Trustees of Boston University
    Inventors: Hugues J. P. Ryser, Wei-Chiang Shen
  • Patent number: 4847070
    Abstract: Disclosed are oral compositions which are effective against calculus and contain a chelating agent which is an acrylic acid polymer or copolymer or EDTA, a strontium ion source, a fluoride ion source and a pyrophosphate ion source.
    Type: Grant
    Filed: October 8, 1987
    Date of Patent: July 11, 1989
    Assignee: The Procter & Gamble Company
    Inventors: Joseph W. Pyrz, Anthony C. Lanzalaco, Richard J. Sunberg
  • Patent number: 4845075
    Abstract: Dimeric proteins having substantially the same biological activity as PDGF are disclosed. More specifically, the protein may have two substantially identical polypeptide chains, each of the chains being substantially homologous to the B-chain of PDGF. Alternatively, the protein may have two polypeptide chains that are substantially identical to the B-chain of PDGF. In addition, proteins comprising polypeptides that are variants or derivatives of the B-chain of PDGF are also disclosed. Therapeutic compositions containing these proteins and methods for enhancing the wound-healing process in warm-blooded animals are also disclosed.
    Type: Grant
    Filed: December 15, 1986
    Date of Patent: July 4, 1989
    Assignee: ZymoGenetics, Inc.
    Inventors: Mark J. Murray, James D. Kelly
  • Patent number: 4845076
    Abstract: There are described DNA sequences from the genome of mammals, in particular from the human genome, coding for proteins having the biological activity of HUSI-type I inhibitors. There are further described biotechnological methods of the preparation of proteins having the biological activity of HUSI-type I inhibitors as well as pharmaceutical compositions containing said proteins.
    Type: Grant
    Filed: January 9, 1987
    Date of Patent: July 4, 1989
    Assignee: Grunenthal GmbH
    Inventors: Regina Heinzel, Heribert Appelhans, Hans G. Gassen, Werner Machleidt, Ursula Seemuller
  • Patent number: 4845194
    Abstract: An improvement in the large-scale recovery of vancomycin-type glycopeptide antibiotics which comprises (1) commingling the fermentation medium in which the antibiotic is produced with a polystyrene divinylbenzene resin such as Dow XFS-43278.00, (2) separating the resin from the medium and (3) eluting the antibiotic from the resin. This improvement avoids preliminary filtration and pH adjustment of the broth, simplifies waste-disposal problems and eliminates antibiotic losses due to mycelial adsorption and filtration.
    Type: Grant
    Filed: February 27, 1987
    Date of Patent: July 4, 1989
    Assignee: Eli Lilly and Company
    Inventors: Suzanne L. E. Glass, Charles W. Johnson, John L. Spencer
  • Patent number: 4845079
    Abstract: A renin inhibiting compound of the formula: ##STR1## wherein A is a substituent; W is C.dbd.O or CHOH; U is CH.sub.2 or NR.sub.2, provided that when W is CHOH then U is CH.sub.2 ; R.sub.1 is loweralkyl, cycloalkylmethyl, benzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)methyl, (2-napththyl)methyl, (4-imidazoyl)methyl, .alpha.,.alpha.-dimethylbenzyl, 1-benzyloxyethyl, phenethyl, phenoxy, thiophenoxy or anilino; R.sub.2 is hydrogen or loweralkyl; R.sub.3 is loweralkyl, [(alkoxy)alkoxy]alkyl, (thioalkoxy)alkyl, loweralkenyl, benzyl or heterocyclic ring substituted methyl; R.sub.4 is loweralkyl, cycloalkylmethyl or benzyl; R.sub.5 is vinyl, formyl, hydroxymethyl or hydrogen; R.sub.7 is hydrogen or loweralkyl; R.sub.8 and R.sub.9 are independently selected from OH and NH.sub.2 ; and R.sub.6 is hydrogen, loweralkyl, vinyl or arylalkyl; provided that when R.sub.5 and R.sub.7 are both hydrogen and R.sub.8 and R.sub.9 are OH, the carbon bearing R.sub.5 is of the "R" configuration and the carbon bearing R.sub.
    Type: Grant
    Filed: July 11, 1988
    Date of Patent: July 4, 1989
    Inventors: Jay R. Luly, Jacob J. Plattner, Dale J. Kempf
  • Patent number: 4843064
    Abstract: The invention provides peptides which are particularly potent in stimulating the release of pituitary GH in fish and amphibians and which have a substantial portion or all of the following sequence: His-Ala-Asp-Gly-R.sub.5 -Phe-Asn-Lys-Ala-Tyr-Arg-Lys-Ala-Leu-Gly-Gln-Leu- Ser-Ala-Arg-Lys-Tyr-Leu-His-Thr-Leu-R.sub.27 -R.sub.28 -R.sub.29 -R.sub.30 -R.sub.31 -Gly-R.sub.33 -R.sub.34 -R.sub.35 -R.sub.36 -R.sub.37 - R.sub.38 -R.sub.39 -R.sub.40 -R.sub.41 -R.sub.42 -R.sub.43 -R.sub.44 -Ser wherein R.sub.5 is Met, Leu, Val, Nva, Gln, Thr, Ile or Nle; R.sub.27 is Met, Leu, Val, Nva, Gln, Thr, Ile or Nle; R.sub.28 is Ala, Ser or Asn; R.sub.29 is Lys or Arg; R.sub.30 is Arg or Gln; R.sub.31 is Val or Gln; R.sub.33 is Gly or Glu; R.sub.34 is Gly, Arg or Ser; R.sub.35 is Ser or Asn; R.sub.36 is Met, Leu, Val, Nva, Gln, Thr, Ile or Nle; R.sub.37 is Ile or Glu; R.sub.38 is Glu, Gln or Arg; R.sub.39 is Asp, Arg or Gly; R.sub.40 is Asp, Ser or Ala; R.sub.41 is Asn, Arg or Lys; R.sub.42 is Glu, Phe, Ala or Val; R.sub.
    Type: Grant
    Filed: September 11, 1987
    Date of Patent: June 27, 1989
    Assignee: The Salk Institute for Biological Studies
    Inventors: Joan Vaughan, Joachim Spiess, Jean E. F. Rivier, Wylie W. Vale, Jr.
  • Patent number: 4840785
    Abstract: A mammal intestinal hormone precursor having the following peptide structure: His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-L-M-Ala-Arg-Leu-Gl n -Arg-Leu-Leu-Gln-Gly-Leu-Val-Gly-N-O, wherein L is Glu or Asp, M is Gly or Ser, and N and O are selected from Lys and Arg; compositions containing such precursor and a method of stimulating pancreatic secretion.
    Type: Grant
    Filed: November 10, 1986
    Date of Patent: June 20, 1989
    Assignee: Kabigen AB
    Inventors: Guro Gafvelin, Mats Carlquist, Viktor Mutt
  • Patent number: 4840772
    Abstract: The present invention relates to ophthalmological pharmaceutical compositions comprising (benzothiadiazine, benzamide and benzenesulfonyl)phenyl-substituted carboxyalkyl dipeptide compounds and to methods for using said composition in reducing intraocular pressure, e.g., in the treatment of glaucoma.
    Type: Grant
    Filed: August 3, 1988
    Date of Patent: June 20, 1989
    Assignee: Schering Corporation
    Inventors: Robert Watkins, Ronald J. Doll, Bernard R. Neustadt, Elizabeth M. Smith, Charles V. Magatti, Elijah H. Gold
  • Patent number: 4840935
    Abstract: The present invention relates to peptide amino-alcohol derivatives containing a tetra substituted carbon atom. Said peptides inhibit the renin and acid proteases. The invention also relates to the process for their obtention and to pharmaceutical compositions.
    Type: Grant
    Filed: July 16, 1986
    Date of Patent: June 20, 1989
    Assignees: Sanofi, Institut National de la Sante et de la Recherche Medicale
    Inventors: Jean Wagnon, Remy Guegan, Colette LaCour, Dino Nisato
  • Patent number: 4839341
    Abstract: This invention provides an insulin formulation stabilized against aggregation containing a hydroxybenzene and a polyethylene glycol-polypropylene glycol polymer of the formula ##STR1## having an average molecular weight of about 8350 and in which the average number of ethyleneoxy units per molecule, designated by the sum of a and c, is about 150, and the average number of propyleneoxy units per molecule, designated as b, is about 30.
    Type: Grant
    Filed: November 13, 1987
    Date of Patent: June 13, 1989
    Assignee: Eli Lilly and Company
    Inventors: Eddie H. Massey, Theodore A. Sheliga
  • Patent number: 4839465
    Abstract: Di(D-tryptophyl and/or tetrahydropyridoindolylcarbonyl)-containing peptide amides useful as Substance P agonists and/or antagonists and as antihypertensives and/or analgesics and a process for preparing them are disclosed.
    Type: Grant
    Filed: January 20, 1987
    Date of Patent: June 13, 1989
    Assignee: Sterling Drug Inc.
    Inventors: Jasbir Singh, Barry A. Morgan
  • Patent number: 4839342
    Abstract: The present invention provides a method of treating an aqueous-deficient dry eye state in a patient suffering therefrom, which method includes the step of administering cyclosporin topically to the patient's eye. The cyclosporin is administered as a solution, suspension or ointment in a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: September 3, 1987
    Date of Patent: June 13, 1989
    Assignee: University of Georgia Research Foundation, Inc.
    Inventor: Renee Kaswan
  • Patent number: 4839343
    Abstract: Preparation containing hexatriacontapeptides suitable for intravenous administration to human or other animal subjects are disclosed. such compositions are effective in treating life-threatening hypotension as encountered in bacteremic, anaphylactic or cardiogenic shock.
    Type: Grant
    Filed: March 13, 1987
    Date of Patent: June 13, 1989
    Assignee: Debiopharm, S.A.
    Inventors: Bernard Waeber, Hans R. Brunner
  • Patent number: 4839357
    Abstract: Peptides of the formula: ##STR1## which comprise novel elements replacing the Phe(8)-His(9) sequence in renin-inhibitory peptides based on substrate analogy, which inhibit the substrate-cleaving action of renin and have improved bioavailability; compositions containing these renin-inhibitory peptides, optionally with other antihypertensive agents; and methods of treating hypertension or congestive heart failure or of establishing renin as a causative factor in these problems which employ the novel peptides.
    Type: Grant
    Filed: October 2, 1987
    Date of Patent: June 13, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Arthur A. Patchett, William J. Greenlee, William H. Parsons, Prasun K. Chakravarty
  • Patent number: 4839464
    Abstract: A composition which can bind heparin and promote cellular adhesion and neurite outgrowth is provided which consists essentially of a polypeptide of the formula:tyr-glu-lys-pro-gly-ser-pro-pro-arg-glu-val-val- pro-arg-pro-arg-pro-gly-val,lys-asn-asn-gln-lys-ser-glu-pro-leu-ile-gly-arg- lys-lys-thr-asp-glu-leu, or mixtures thereof.Medical devices such as prosthetic implants, percutaneous devices and cell culture substrates coated with the polypeptide composition are also provided.
    Type: Grant
    Filed: August 25, 1987
    Date of Patent: June 13, 1989
    Assignee: Regents of the University of Minnesota
    Inventors: James B. McCarthy, Leo T. Furcht
  • Patent number: 4839344
    Abstract: Disclosed are novel polypeptide compounds which promote the release and elevation of growth hormone levels in the blood of animals. Also disclosed are methods of promoting the release and elevation of growth hormone levels in the blood of animals using the disclosed polypeptide compounds.
    Type: Grant
    Filed: June 12, 1987
    Date of Patent: June 13, 1989
    Assignee: Eastman Kodak Company
    Inventors: Cyril Y. Bowers, Frank A. Momany, Ching H. Chang, Wayne L. Cody, John C. Hubbs, Charles H. Foster
  • Patent number: 4837022
    Abstract: A composition containing a tissue Plasminogen Activator (tPA) which comprises a partial hydrolyzate of gelatin cross-linked to a diisocyanate as an essential ingredient; or alternatively a partial hydrolyzate of gelatin cross-linked to a diisocyanate and one or more of a basic amino acid or salt thereof. The composition enhances the solubility of the tPA in water, thereby making the tPA further available in the treatment of circulatory diseases caused by thrombi.
    Type: Grant
    Filed: September 10, 1986
    Date of Patent: June 6, 1989
    Assignee: Eisai Co., Ltd.
    Inventors: Fumio Kakimoto, Naoki Asakawa, Yasuo Ishibashi, Yasuo Miyake
  • Patent number: 4837204
    Abstract: The invention relates to renin inhibiting compounds of the formula ##STR1## wherein A is hydrogen; loweralkyl; aryalkyl; OR.sub.8 or SR.sub.8 wherein R.sub.8 is hydrogen, loweralkyl or aminoalkyl; NR.sub.9 R.sub.10 wherein R.sub.9 and R.sub.10 are independently selected from hydrogen, loweralkyl, aminoalkyl, cyanoalkyl and hydroxyalkyl; ##STR2## wherein B is NH, alkylamino, S, O, CH.sub.2 or CHOH and R.sub.11 is loweralkyl, cycloalkyl, aryl, arylalkyl, alkoxy, alkenyloxy, hydroxyalkoxy, dihydroxyalkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, (hydroxyalkyl)(alkyl)amino, (dihydroxyalkyl)(alkyl)amino, carboxylic acid-substituted alkyl, alkoxycarbonylalkyl, aminoalkyl, N-protected aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (N-protected)-(alkyl)aminoalkyl, (heterocyclic)alkyl or a substituted or unsubstituted heterocyclic; R.sub.1 is loweralkyl, cycloalkylmethyl, benzyl, .alpha.-methylbenzyl, .alpha.,.alpha.
    Type: Grant
    Filed: May 9, 1988
    Date of Patent: June 6, 1989
    Assignee: Abbott Laboratories
    Inventors: Saul H. Rosenberg, Jay R. Luly, Jacob J. Plattner